Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109-1024, USA.
Expert Rev Respir Med. 2011 Feb;5(1):127-35. doi: 10.1586/ers.10.79.
Bronchiolitis obliterans syndrome is a potentially fatal complication of allogeneic hematopoietic cell transplantation that is defined as the development of new fixed airflow obstruction within the first 2 years after transplantation. The prevalence of this syndrome is estimated to be 5.5% among all allogeneic hematopoietic cell transplantation recipients, and 14% among all long-term survivors who develop chronic graft-versus-host disease. Although little is known about the pathogenesis of this syndrome, there are now clear guidelines for clinical diagnosis of bronchiolitis obliterans syndrome, and there appear to be promising new approaches towards treatment that can significantly reduce the morbidity associated with corticosteroid therapy. Future research efforts should target the identification of clinical biomarkers for risk stratification, early diagnosis and treatment-response assessment.
闭塞性细支气管炎综合征是异基因造血细胞移植的一种潜在致命并发症，其定义为移植后 2 年内出现新的固定气流阻塞。据估计，该综合征在所有异基因造血细胞移植受者中的患病率为 5.5%，在所有发展为慢性移植物抗宿主病的长期幸存者中患病率为 14%。尽管对于这种综合征的发病机制知之甚少，但现在已经有明确的临床诊断闭塞性细支气管炎综合征的指南，并且似乎有很有前途的新治疗方法，可以显著降低与皮质类固醇治疗相关的发病率。未来的研究工作应针对确定临床生物标志物进行风险分层、早期诊断和治疗反应评估。
